[A case study; ethnicity and clozapine, a risky combination?]

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Agranulocytosis is a severe adverse effect of clozapine, necessitating strict monitoring of leukocyte and neutrophil counts.
• Dutch guidelines mandate specific blood count thresholds for discontinuing clozapine therapy due to agranulocytosis risk.

Observation:

• The study focuses on a patient diagnosed with benign ethnic neutropenia, characterized by persistently low neutrophil counts.
• This patient continued clozapine treatment despite neutrophil counts below the typical threshold for discontinuation.

Findings:

• Interpreting neutrophil counts requires considering individual patient factors, such as benign ethnic neutropenia.
• Deviation from standard interpretation guidelines may be warranted in specific clinical contexts.

Implications:

• Clinical practice should incorporate nuanced interpretation of blood counts for patients on clozapine, especially those with pre-existing conditions.
• Individualized patient assessment is crucial for balancing the benefits of clozapine with the risk of agranulocytosis.